Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. - Wikidata - wikimedia - TriplyDB

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.

http://www.wikidata.org/entity/Q45221750

about

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Advances in the treatment of invasive neonatal candidiasis Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Posaconazole: an oral triazole with an extended spectrum of activity Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.Human pharmacogenomic variations and their implications for antifungal efficacy.Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration Posaconazole: clinical pharmacology and potential for management of fungal infections.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole Developments in the treatment of candidiasis: more choices and new challenges.Posaconazole: a new broad-spectrum antifungal agent.Posaconazole in the management of refractory invasive fungal infections.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Pediatric antifungal agents.Use of posaconazole in the treatment of invasive fungal infections.Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.Therapeutic drug monitoring of voriconazole and posaconazole.Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation.Posaconazole: when and how? The clinician's view.Safety of posaconazole.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis.Posaconazole: a next-generation triazole antifungal.Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs.Posaconazole (Noxafil): a new triazole antifungal agent.Role of posaconazole in the treatment of oropharyngeal candidiasis Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.Posaconazole: An Update of Its Clinical Use.Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

P2860

Q26782472-74086670-1B48-4128-835F-357AE7071658 Q27009221-8C832368-CB68-4FD0-AE53-002034E3AE12 Q27022585-A46A7D92-53FA-4A59-B1D3-2D96058FFFE0 Q27025299-BD495FB6-83AE-4AAE-BC55-071AEA3C25D9 Q28291282-F7635B66-AA45-4708-8ACA-16D776A9356A Q34108650-15436A28-ACA1-4DA1-BB0B-596E9A6C9E32 Q34309527-30F9404A-92CD-48D1-A7ED-BBB2D079D8E3 Q34352014-D7707B00-2E49-4FCC-8C65-05C98D5659F2 Q34648517-B8C8DCF2-EC9B-4898-89AE-3F45A6EE54F4 Q35070838-8D91B136-BD34-4D02-985A-9437D307F609 Q35635971-8BB51E30-A946-4825-87BB-9ADC93E9B9E5 Q36018743-C0934DFF-A599-4956-8236-D8F1D2E7B904 Q36076106-EA24D076-1E52-4583-B8E0-4E58EEEA5DB0 Q36233491-3370CADC-0258-4B92-9E70-CA4613864FDC Q36521993-EE7882BF-DCE6-49C2-A0EA-DCA960B62EFF Q36623050-81B0B8C9-B89C-4E45-A42B-E10898D385C9 Q36828159-46675855-04FB-44BF-B813-625DFCE7587B Q37052755-5A7EA390-2788-4CA8-8A32-0827EE03EED0 Q37055215-CF5B1D57-9BEC-49C4-978D-B432774B6FF6 Q37072036-6F5CB7E5-36C3-4012-B7AF-CE2BC2A1B1B4 Q37404840-71E0B1D7-A8EF-4F09-957F-4C43B194C782 Q37594515-1341A567-560A-4BB5-B65F-2A867CAECAB5 Q37810083-57CBFE62-ECE2-4189-8798-688065179B3A Q37813420-48C2CF1F-3050-4C53-A35D-FA59C8E67A91 Q37833074-51B482F3-1BCC-4F1C-8EC9-120D83F21983 Q37854721-FA5A5CD5-FA0E-489B-9F69-FF685719D4D5 Q37901534-44743219-202A-48CC-9BFD-971AC3B3B719 Q38077591-CD3FFB36-99EE-43D5-BC4D-E154698599E1 Q38681635-913482AA-2315-4EA6-906C-D6779DDCD5D8 Q38775583-17F7C9BD-C485-4D83-B4D4-A68A68894556 Q40188974-383A3338-E789-4FF4-B10F-BC27633DD186 Q40323166-D1DC8708-F9E1-49B2-B4D7-2B92BDBDFC78 Q40452729-FAA2C030-6ED0-4F38-969D-8DDFD44EAB21 Q41842051-3A3924C9-C432-41B7-B21E-3C10799C40E2 Q41848545-DFB944B2-D7D0-406E-8FCB-60DDCE7C5D82 Q42144246-4B8B042A-4FFC-47EF-A241-04DF36D11A83 Q42413286-40C98F47-F71C-4CB4-A676-0598665E02CE Q42572410-93842414-FA68-4B7E-A5B2-9B1949CF08A4 Q42686004-85267AF4-857A-4BAA-B455-9A0D1BFF792D Q46341880-24B3D247-5D71-45A8-BF23-605EFE566B99

P2860

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.

http://www.wikidata.org/entity/Q45221750

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Posaconazole pharmacokinetics, ...... rees of chronic renal disease.

@en

Posaconazole pharmacokinetics, ...... rees of chronic renal disease.

@nl

type

label

Posaconazole pharmacokinetics, ...... rees of chronic renal disease.

@en

Posaconazole pharmacokinetics, ...... rees of chronic renal disease.

@nl

prefLabel

Posaconazole pharmacokinetics, ...... rees of chronic renal disease.

@en

Posaconazole pharmacokinetics, ...... rees of chronic renal disease.

@nl

P1433

Q45221750-02BBC582-2FAB-440E-87DA-FA42B00F5E1B

P1476

Q45221750-817FA7D6-2304-4F94-BBE6-2EE1481D9564

P2093

Q45221750-1AE1335A-BD42-4998-9DE0-864DCFEA9381

Q45221750-205A5D76-22EC-41AE-ADF6-94D81B4663D6

Q45221750-2783C741-4173-4B9E-951F-76B77D9B0D78

Q45221750-344E5531-C7DC-4FCD-84CD-34230DFA5222

Q45221750-7A24DB0A-D268-435E-BF8B-01372F057678

Q45221750-A13D2F28-E83C-4AA9-8AC2-6342DDF31A3A

Q45221750-D1D3AB8F-2535-460A-A4D3-22E4078C4DB9

Q45221750-DA78EB20-7859-488B-9AAB-F0800DBB6A8C

P2860

Q45221750-027DF82D-C0CD-4635-8AC5-A05C20ECCDE7

Q45221750-0416DD6B-3C1C-4715-BBCC-F35A18CA0E2F

Q45221750-51D46299-17C9-49F8-8EC1-7679A8C16A18

Q45221750-6871B8C1-7E83-4DA6-98E9-9CB932507BEE

Q45221750-839DEA48-E5EA-44E2-92A5-3B19A5F16A44

Q45221750-92FB92DC-0253-4A3B-B486-4F426C31E20D

Q45221750-93CA129B-969B-481B-B638-CDB4186C5D67

Q45221750-A6432556-0F58-4021-9AAA-6E21C829A9CE

Q45221750-B07A734B-EC78-428B-9596-E3BE6AA753E5

Q45221750-D1268470-B839-4138-B4D9-737E117DC8AF

P304

Q45221750-0878F682-BF72-4B81-8433-5308658D09D3

P31

Q45221750-7BB88929-8FAB-4AD6-AAE0-1319B27B1817

P356

Q45221750-7DB6027E-EE63-4455-BE62-A34126F02DBF

P433

Q45221750-CB9DEC70-A375-471B-9AD9-5CC1C867E489

P478

Q45221750-4D5C09AC-32CA-4813-8C3F-45E301774A96

P577

Q45221750-8814FD34-F746-4CC3-891A-25E7CDB01136

P698

Q45221750-B3636338-2B76-4929-B959-895A8C56B4F4

P356

0091270004271402

P1433

The Journal of Clinical Pharmacology

P1476

Posaconazole pharmacokinetics, ...... rees of chronic renal disease.

@en

P2093

A Sansone

http://www.w3.org/2001/XMLSchema#string

M Laughlin

http://www.w3.org/2001/XMLSchema#string

M Martinho

http://www.w3.org/2001/XMLSchema#string

P Statkevich

http://www.w3.org/2001/XMLSchema#string

R Courtney

http://www.w3.org/2001/XMLSchema#string

S Swan

http://www.w3.org/2001/XMLSchema#string

T Marbury

http://www.w3.org/2001/XMLSchema#string

W Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

Amphotericin B nephrotoxicity.

Antifungal use in HIV infection.

Review of the safety and efficacy of voriconazole.

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Disposition of posaconazole following single-dose oral administration in healthy subjects.

Fungal infections in solid-organ transplantation.

P304

185-192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270004271402

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15647411

http://www.w3.org/2001/XMLSchema#string